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The ethyl acetate extract from the Streptomyces sp. isolate B8652 delivered the trioxacarcins A-C (2a ~ 2c) and additionally three new derivatives designated as trioxacarcins D-F (2d ~ 2f). All trioxacarcins showed high anti-bacterial and some of them high anti-tumor and anti-malaria activity. The structures of the new antibiotics were derived from mass, 1D and 2D NMR spectra and confirmed by comparison of the NMR data with those of known derivatives. The absolute configuration of the trioxacarcins is deduced from the X-ray analysis of gutingimycin (2g) and from the known stereochem- Trioxacarcins are complex antibiotics isolated first in 1981 by Tomita et al. 1) and elucidated in the following year by Shirahata et al. 2) . Trioxacarcins A (2a), B (2b) and C (2c) were obtained from S. ochraceus and also S. bottropensis, trioxacarcin A 1 (O 13 -deglyco-trioxacarcin A) and A 2 (O 4 ,O 13 -deglyco-trioxacarcin A), however, only from the latter. Trioxacarcins are cytotoxic against various cancer cell lines and are also active against Grampositive and Gram-negative bacteria, the trioxacarcins A 1 and A 2 exhibit also antifungal activity.
In the course of our screening program for novel bio-active compounds from marine Streptomycetes, the ethyl acetate extract of the marine Streptomyces sp. isolate B8652
3) drew our attention due to various yellow bands on TLC, which showed an intensive green fluorescence under UV light and gave a grey colouration with anisaldehyde/sulphuric acid. In addition, high biological activity against Staphylococcus aureus, Escherichia coli, Bacillus subtilis, and Streptomyces viridochromogenes Tü 57 deserved further interest. Purification of the nonpolar fraction afforded parimycin 3) (1), while the middle polar fraction delivered the known trioxacarcins A ~ C (2a ~ 2c) and the new derivatives D ~ F (2d ~ 2f). The polar fraction delivered a novel structure which we named gutingimycin 4) (2g). We also discovered a so far unknown high anti-malaria activity of the trioxacarcins. In this paper we report on the isolation, the structure elucidation and the bio-activity of the trioxacarcins A ~ F (2a ~ 2f) and the bio-activity of gutingimycin (2g).
Fermentation and Isolation
The taxonomic properties and the fermentation of Streptomyces sp. isolate B8652 have been reported previously 3) . The crude extract, obtained after usual work-up of 20 L of culture broth, was subjected to flash chromatography on silica gel with a MeOH/CHCl 3 gradient. The fraction I contained only fats and was not further analysed. A second yellow, green fluorescent fraction II delivered parimycin 3) (1). The following fractions III ~ V were highly active in the agar diffusion test against Staphylococcus aureus, Escherichia coli, Bacillus subtilis, and Streptomyces viridochromogenes Tü 57. Further separation of these fractions yielded mainly trioxacarcin A (2a), and the minor components 2b ~ 2f as light yellow solids. The highly polar fraction VIII contained a compound designated as gutingimycin (2g). 
Gutingimycin

Results and discussion
The colour, the fluorescence under 366 nm and the 1 H NMR spectrum of the yellow compound 2a indicated similarities with the data of parimycin (1) . A chelated hydroxy group gave an H/D exchangeable 1H singlet at δ 14.06 and the aromatic region showed a singlet at δ 7.49. The signals between δ 6.0 ~ 4.0 could be assigned to the presence of additional sugar moieties in the molecule. The proton and 13 C NMR spectra of compound 2b showed very close similarities with those of compound 2a, except that the proton signals at δ 2.98 and 2.89 of a methylene group were shifted to δ 3.75 and the corresponding methylene carbon signal at δ 48.2 were shifted to lower field as well. The molecular weight, derived from the ESI mass spectrum, was 18 units higher than that of compound 2a, which indicated compound 2b to contain an additional molecule of water.
The 1 H and 13 C NMR spectra of compound 2c were again very similar to those of compound 2a. The only deviation was an additional 1H quartet at δ 3.93 and a 3H doublet in the region δ 1.40 ~ 1.20 instead of the methyl singlet at δ 2.46. In the 13 C NMR spectrum, the carbonyl signal at δ 210.3 was missing and an additional signal in the aliphatic region was detected. The missing ketone signal and the additional 2 mass units compared with compound 2a indicated that the ketone group in the sugar moiety of compound 2a had been reduced to an alcohol.
The search in AntiBase 5) with these data led to the trioxacarcins A ~ C 1,2) (2a ~ 2c) and to the closely related antibiotics of the LL-D49194 group 6) , where the residue at C-13 in the 2 series and one of the methoxy groups at C-16 are exchanged. Therefore the structures were controlled by 2D experiments ( Fig. 2 and 3 ) which confirmed, however, structures 2a ~ 2c. Compound 2d exhibited the same characteristic properties as shown by 2a ~ 2c. Comparison of the proton spectrum of this substance with that of 2a demonstrated identity except for a missing acetate signal at δ 2.11. In the 13 Fig. 2 and 3 ) and the new derivative was named as trioxacarcin D.
Similarly, compound 2e was obtained as a yellow solid showing the same green fluorescence at 366 nm and a grey colouration with anisaldehyde/sulphuric acid, and the 1 H NMR spectrum was again typical for trioxacarcins. Some sugar signals between δ 5.0 ~ 4.0, the CH 2 signal of the epoxide, a methyl singlet at δ 2.4 and a doublet at 1.3, however, were missing. In the 13 C NMR spectrum, among others, a ketone signal and anomeric carbon signals of the acetyl sugar were missing. Obviously one sugar residue must have got lost, presumably that at C-13, resulting in the unknown O 13 -deglycotrioxacarcin B with a mass of 722. As the observed molecular weight of compound 2e (m/z 740) demands one additional mol of water, the acetal bond between C-11 and C-15 in 2b must be hydrolysed.
In the HMBC spectrum, 12-H and C-15, but not 11-H and C-15, were coupling together, thus confirming the expectation. Also all other correlations were fitting with the new structure 2e, which we designated as trioxacarcin E.
Due to its chemical characteristics and the 1 H NMR and MS data, compound 2f was a further trioxacarcin derivative. The compound decomposed, however, in chloroform under the influence of light and no 13 C and 2D NMR spectra could be measured. The molecular weight of 912 (ESI MS) was 18 units higher than that of trioxacarcin B (2b). The similarity of the proton signals (see Table 1 ) with those of trioxacarcin E (2e) indicated that also here the acetal bond between C-11 and C-15 must have been hydrolysed giving trioxacarcin F (2f).
The X-ray structure of gutingimycin 4) (2g) delivered the relative stereochemistry of the trioxacarcin skeleton. As the sugar moieties of the trioxacarcins A (2a) and B (2b) had been identified previously as L-trioxacarcinoses A and B 2) , the absolute configuration of trioxacarcin A ~ F (2a ~ 2f) is established now as shown in formulae 2a ~ 2g. It should be mentioned that the trioxacarcins are closely related with the antibiotics of the LL-D49194 group 7 , where the residue at C-13 in the 2 series and one of the methoxy groups at C-16 are exchanged. Table 3 . In the agar diffusion tests, trioxacarcins A ~ E (2a ~ f) and gutingimycin (2g) showed comparable activities, trioxacarcins A (2a) and D (2d) being the most active of all. In tests with the same microorganisms as in Table 3 using liquid medium, the trioxacarcins were found to be highly active with MIC values 0.15 ~ 2.5 µg/ml as compared to gutingimycin (2g) with MIC values > 20 µg/ml. All the compounds were inactive, however, against the fungi Candida albicans and Mucor miehei and the micro-algae Chlorella vulgaris, Chlorella sorokiniana and Scenedesmus subspicatus 
Staphylococcus aureus
In addition, the trioxacarcins A-D (2a ~ 2d) and gutingimycin (2g) were tested against Plasmodium falciparum. Trioxacarcin A (2a) and D (2d) possessed extremely high antiplasmodial activity which was comparable to the most active compound, artemisinin. Trioxacarcin B (2b) was about 100 times less active than trioxacarcin A (2a) and D (2d), and trioxacarcin C (2c) and gutingimycin (2g) were nearly inactive. The results of the tests are listed in Table 4 . ~ 2d) showed selective antitumor activity against certain tumor cell lines. Gutingimycin (2g) was clearly less active than 2a with a mean IC 70 -value of 3.386 µg/ml and had no pronounced antitumor selectivity (table 5) . The inhibiting effect of the test compounds on the growth of tumor stem cells to colonies was in addition investigated in a clonogenic assay. Tumor stem cells, which are responsible for the metastatic and infiltrative potential of a tumor, were prepared directly from solid human tumor xenografts growing in nude mice. Hence, the clonogenic assay reflects better the in vivo situation than in vitro assays using permanent tumor cell lines and has been found to be the most predictive test for further invivo evaluation of anticancer drugs 8, 9, 10) . The antitumor activity of the trioxacarcins A ~ D (2 a ~ d) on the large cell lung cancer tumor model LXFL 529 could be confirmed in this assay. IC 70 -values obtained there ranged from 0.16 ng/ml (trioxacarcin A), 25.0 ng/ml (trioxacarcin B), 0.33 ng/ml (trioxacarcin C) to 5.0 ng/ml (trioxacar cin D), whereas gutingimycin (2 g) did not show pronounced antitumor activity in this assay (IC 70 > 10.0 µg/ml) (table 6). Trioxacarcin A (2a) also proved to be very toxic in preliminary in vivo experiments in tumor bearing nude mice. The maximum tolerated dose (MTD) was found to be between 0.1 and 0.3 mg/kg, given i.p. In an anti-viral test against the picornavirus EMC 11) , parimycin (1), trioxacarcin A ~ D (2a ~ 2d) and gutingimycin (2g) were found to be inactive to protect human A549 cells from virus lysis. 
Experimental
Material & methods and antimicrobial tests were used as described earlier 12) .
Antitumor Test
Human Tumor Cell Lines Effects of the test compounds on the proliferation of human tumor cells were determined in an assay where human tumor cell lines, growing as monolayers were treated with the test compounds and surviving cells were stained with a fluorescence dye. Details of the test procedure have been described earlier 13) .
Human Tumor Xenografts Effects of the test compounds on tumor stem cells was investigated in a clonogenic assay, where inhibition of colony formation of tumor stem cells growing in soft agar is examined. Details of the test procedure have been described recently 10) .
Anti-plasmodia Test Antiplasmodial activity was determined using the NF54 strain of P. falciparum of unknown origin, first isolated at the Amsterdam airport and the K1 strain from Thailand. While strain NF54 displays normal sensitivity to all known antiplasmodial drugs, strain K1 is resistant to chloroquine and pyrimethamine. A modification of the [ 3 H]-hypoxanthine incorporation assay was used for determining intra-erythrocytic inhibition of parasite growth. Briefly, P. falciparum-infected human red blood cells in hypoxanthine-deficient culture medium (see above) were exposed to serial drug dilutions in microtiter plates for 48 hours at 37 °C in a 4% CO 2 -enriched humidified atmosphere before [ 3 H]-hypoxanthine was added for another 24 h and its incorporation by viable parasites assessed. The drug concentration at which growth was inhibited by 50 % (IC 50 ) was calculated by linear interpolation between the two drug concentrations above and below the 50 % incorporation line. Chloroquine (10 mg/ml in stock solution) and artemisinin (10 mg/ml (CH 2 -3), 36.6 (CH 2 -2'), 25.7 (3'-CH 3 ), 20.9 (6-CH 3 ), 20.2 (4'-OCOCH 3 ), 14.6 (5'-CH 3 ).
Trioxacarcin F (2f) R f = 0.55 (CHCl 3 /10 % MeOH). -1 H NMR (CDCl 3 , 500 MHz) see tab. 1.
